Literature DB >> 19153716

Comparison of the discriminative stimulus effects of salvinorin A and its derivatives to U69,593 and U50,488 in rats.

Lisa E Baker1, John J Panos, Bryan A Killinger, Mary M Peet, Lisa M Bell, Larissa A Haliw, Sheryl L Walker.   

Abstract

BACKGROUND AND RATIONALE: Research interests regarding the psychopharmacology of salvinorin A have been motivated by the recreational use and widespread media focus on the hallucinogenic plant, Salvia divinorum. Additionally, kappa opioid (KOP) receptor ligands may have therapeutic potential in the treatment of some neuropsychiatric conditions, including drug dependence and mood disorders. Salvinorin A is a selective KOP agonist, but only a few studies have explored the discriminative stimulus effects of this compound.
OBJECTIVE: This study compared the discriminative stimulus effects of salvinorin A and two synthetic derivatives of salvinorin B to the KOP agonists, U69,593 and U50,488.
MATERIALS AND METHODS: Sixteen male Sprague-Dawley rats trained to discriminate U69,593 (0.13 mg/kg, s.c., N = 8) or U50,488 (3.0 mg/kg, i.p., N = 8) under a fixed-ratio 20 schedule of food reinforcement were administered substitution tests with salvinorin A (0.125-3.0 mg/kg, i.p.). The animals trained to discriminate U69,593 were also administered substitution tests with salvinorin B ethoxymethyl ether (0.005-0.10 mg/kg, i.p.) and salvinorin B methoxymethyl ether (0.03-0.10 mg/kg, i.p.). Another eight rats were trained to discriminate 2.0 mg/kg salvinorin A and tested with U69,593 (0.04-0.32 mg/kg) and U50,488 (0.4-3.2 mg/kg).
RESULTS: Salvinorin A and both synthetic derivatives of salvinorin B substituted completely for U69,593. Additionally, cross-generalization was observed between salvinorin A and both KOP agonists.
CONCLUSION: These findings support previous reports indicating that the discriminative stimulus effects of salvinorin A are mediated by kappa receptors. Future studies may assist in the development and screening of salvinorin A analogs for potential pharmacotherapy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19153716     DOI: 10.1007/s00213-008-1458-3

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  29 in total

1.  Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.

Authors:  Christopher R McCurdy; Kenneth J Sufka; Grant H Smith; Jason E Warnick; Marcelo J Nieto
Journal:  Pharmacol Biochem Behav       Date:  2006-01-23       Impact factor: 3.533

Review 2.  Relationship between the discriminative stimulus properties and subjective effects of drugs.

Authors:  C R Schuster; C E Johanson
Journal:  Psychopharmacol Ser       Date:  1988

3.  Potent antinociceptive effects of TRK-820, a novel kappa-opioid receptor agonist.

Authors:  T Endoh; H Matsuura; A Tajima; N Izumimoto; C Tajima; T Suzuki; A Saitoh; T Suzuki; M Narita; L Tseng; H Nagase
Journal:  Life Sci       Date:  1999       Impact factor: 5.037

4.  Ethnopharmacology of ska María Pastora (Salvia divinorum, Epling and Játiva-M.).

Authors:  L J Valdés; J L Díaz; A G Paul
Journal:  J Ethnopharmacol       Date:  1983-05       Impact factor: 4.360

5.  Effects of the plant-derived hallucinogen salvinorin A on basal dopamine levels in the caudate putamen and in a conditioned place aversion assay in mice: agonist actions at kappa opioid receptors.

Authors:  Yong Zhang; Eduardo R Butelman; Stefan D Schlussman; Ann Ho; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2005-01-29       Impact factor: 4.530

6.  Depressive-like effects of the kappa-opioid receptor agonist salvinorin A on behavior and neurochemistry in rats.

Authors:  William A Carlezon; Cécile Béguin; Jennifer A DiNieri; Michael H Baumann; Michele R Richards; Mark S Todtenkopf; Richard B Rothman; Zhongze Ma; David Y-W Lee; Bruce M Cohen
Journal:  J Pharmacol Exp Ther       Date:  2005-10-13       Impact factor: 4.030

7.  Discriminative stimulus effects of 1-(2,5-dimethoxy-4-methylphenyl)-2-aminopropane in rhesus monkeys.

Authors:  Jun-Xu Li; Kenner C Rice; Charles P France
Journal:  J Pharmacol Exp Ther       Date:  2007-11-09       Impact factor: 4.030

8.  Standard protecting groups create potent and selective kappa opioids: salvinorin B alkoxymethyl ethers.

Authors:  Thomas A Munro; Katharine K Duncan; Wei Xu; Yulin Wang; Lee-Yuan Liu-Chen; William A Carlezon; Bruce M Cohen; Cécile Béguin
Journal:  Bioorg Med Chem       Date:  2007-10-24       Impact factor: 3.641

9.  Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations.

Authors:  Charles Chavkin; Sumit Sud; Wenzhen Jin; Jeremy Stewart; Jordan K Zjawiony; Daniel J Siebert; Beth Ann Toth; Sandra J Hufeisen; Bryan L Roth
Journal:  J Pharmacol Exp Ther       Date:  2004-01-08       Impact factor: 4.030

Review 10.  Salvinorin A: a novel and highly selective kappa-opioid receptor agonist.

Authors:  Feng Yan; Bryan L Roth
Journal:  Life Sci       Date:  2004-10-15       Impact factor: 5.037

View more
  24 in total

Review 1.  Clerodane diterpenes: sources, structures, and biological activities.

Authors:  Rongtao Li; Susan L Morris-Natschke; Kuo-Hsiung Lee
Journal:  Nat Prod Rep       Date:  2016-07-18       Impact factor: 13.423

2.  Drug discrimination: 30 years of progress.

Authors:  Joseph H Porter; Adam J Prus
Journal:  Psychopharmacology (Berl)       Date:  2009-02-19       Impact factor: 4.530

3.  The 2-methoxy methyl analogue of salvinorin A attenuates cocaine-induced drug seeking and sucrose reinforcements in rats.

Authors:  Aashish S Morani; Amy Ewald; Katherine M Prevatt-Smith; Thomas E Prisinzano; Bronwyn M Kivell
Journal:  Eur J Pharmacol       Date:  2013-11-04       Impact factor: 4.432

4.  Salvinorin A and derivatives: protection from metabolism does not prolong short-term, whole-brain residence.

Authors:  Jacob M Hooker; Thomas A Munro; Cécile Béguin; David Alexoff; Colleen Shea; Youwen Xu; Bruce M Cohen
Journal:  Neuropharmacology       Date:  2009-07-08       Impact factor: 5.250

Review 5.  Neuropharmacology of the naturally occurring kappa-opioid hallucinogen salvinorin A.

Authors:  Christopher W Cunningham; Richard B Rothman; Thomas E Prisinzano
Journal:  Pharmacol Rev       Date:  2011-03-28       Impact factor: 25.468

6.  Role of kappa-opioid receptors in the effects of salvinorin A and ketamine on attention in rats.

Authors:  Christina L Nemeth; Tracie A Paine; Joseph E Rittiner; Cécile Béguin; F Ivy Carroll; Bryan L Roth; Bruce M Cohen; William A Carlezon
Journal:  Psychopharmacology (Berl)       Date:  2010-04-01       Impact factor: 4.530

7.  Kappa opioid mediation of cannabinoid effects of the potent hallucinogen, salvinorin A, in rodents.

Authors:  D Matthew Walentiny; Robert E Vann; Jonathan A Warner; Lindsey S King; Herbert H Seltzman; Hernán A Navarro; Charles E Twine; Brian F Thomas; Anne F Gilliam; Brian P Gilmour; F Ivy Carroll; Jenny L Wiley
Journal:  Psychopharmacology (Berl)       Date:  2010-03-31       Impact factor: 4.530

8.  The discriminative effects of the kappa-opioid hallucinogen salvinorin A in nonhuman primates: dissociation from classic hallucinogen effects.

Authors:  Eduardo R Butelman; Szymon Rus; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  Psychopharmacology (Berl)       Date:  2010-01-19       Impact factor: 4.530

Review 9.  Strategies for Developing κ Opioid Receptor Agonists for the Treatment of Pain with Fewer Side Effects.

Authors:  Kelly F Paton; Diana V Atigari; Sophia Kaska; Thomas Prisinzano; Bronwyn M Kivell
Journal:  J Pharmacol Exp Ther       Date:  2020-09-10       Impact factor: 4.030

10.  Synthetic studies of neoclerodane diterpenes from Salvia divinorum: role of the furan in affinity for opioid receptors.

Authors:  Denise S Simpson; Kimberly M Lovell; Anthony Lozama; Nina Han; Victor W Day; Christina M Dersch; Richard B Rothman; Thomas E Prisinzano
Journal:  Org Biomol Chem       Date:  2009-07-14       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.